tc i

TC-I 2014 shows antiallodynic properties in pain models. TC-I 2014 is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 antagonist (IC50: 0.8 nM, 3.0 nM, and 4.4 nM for canine, human and rat channels respectively).

α2β1 integrin inhibitor

BCATc Inhibitor 2 exhibited an IC50 of 0.8 microM in the hBCATc assays; it is an active and selective inhibitor. BCATc Inhibitor 2 also blocked calcium influx into neuronal cells following inhibition of glutamate uptake, and demonstrated neuroprotective e

Sphistin Synthetic Peptide (12-38, Fitc in N-Terminal-Fluorescently Labeled Peptide) represents truncated fragments of the parent peptide, characterized by an N-terminal fluorescent label (Fitc).

ICI-204879 HCl is a potent and selective agonists at the opioid kappa-receptor.

Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH).

TC-I2000 is an TRPM8 channel blocker. Inhibits icilin-induced TRPM8 channel activation in rTRPM8-expressing CHO cells with IC50 of 53 nM.